A same‐day assay predicts apoptotic response to combined BCL‐2 and MCL‐1 BH3‐mimetic targeting in multiple myeloma cells

ABSTRACT: Abstract Recent advances in treatment options for multiple myeloma (MM) have positive impact on patient survival. However, there is a short fall of rapid and reliable assays that can predict patient response to novel agents. The anti‐apoptotic proteins B‐cell lymphoma‐2 (BCL‐2) and myeloid cell leukaemia‐1 (MCL‐1), are necessary for MM survival, although most myelomas are more dependent on MCL‐1. BCL‐2 inhibition alone yields significant cytotoxicity in only a minority of cases, therefore targeting both proteins simultaneously, is a therapeutic option. Venetoclax and S63845 are BCL‐2 and MCL‐1 targeting BH3‐mimetics which have demonstrated apoptotic synergy in MM. We investigated whether a novel short‐term flow cytometric cytochrome c release assay could predict response to dual BH3‐mimeti

SUBMITTER: Grundy M 

PROVIDER: S-EPMC9175957 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature